Medtech
Raleigh-based Bryn Pharma adds COO to join new CEO leadership team
Bryn Pharma has appointed a new Chief Operating Officer, the company announced this week. This announcement comes just two weeks after the Raleigh-based…
RALEIGH — Bryn Pharma has appointed a new Chief Operating Officer, the company announced earlier this week. This announcement comes just two weeks after the company named a new CEO.
Raleigh-based Bryn Pharma is a privately held pharmaceutical company focused on creating a new treatment for anaphylaxis, a life-threatening allergic reaction.
Their signature device, UTULY, is a needle-free epinephrine nasal spray that could become an alternative to the commonly-prescribed EpiPen.
According to the press release, the new COO, James “Jim” Borneman, will be responsible for “day-to-day operational oversight” as Bryn prepares for the FDA approval and launch of UTULY.
The release also said that Borneman has participated in multiple new product launches during his career and that his experience in commercialization is expected to be “essential” as Bryn prepares to launch UTULY.
New CEO Sandy Loreaux took over on March 13. The former CEO, Dr. David Dworaczyk, stepped down into a role as senior advisor and head of R&D.
Raleigh-based Bryn Pharma brings on new CEO to help launch EpiPen alternative
The post Raleigh-based Bryn Pharma adds COO to join new CEO leadership team first appeared on WRAL TechWire.
ETF Talk: AI is ‘Big Generator’
Second nature comes alive Even if you close your eyes We exist through this strange device — Yes, “Big Generator” Artificial intelligence (AI) has…
Apple gets an appeals court win for its Apple Watch
Apple has at least a couple more weeks before it has to worry about another sales ban.
Federal court blocks ban on Apple Watches after Apple appeal
A federal appeals court has temporarily blocked a sweeping import ban on Apple’s latest smartwatches while the patent dispute winds its way through…
